Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
Date:6/4/2009

of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limite
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Large scale gene expression studies , ... purify high quality RNA from a large number of samples. Although the , ... both dsRNA production and , clean ... format. Thus for high-throughput applications, we recommend , ...
... with GeneChip , analysis , ... ng RNA in a single round , ... ArrayScript engineered M-MLV RT, engineered to maximize , yields ... synthesis powered by , MEGAscript, the best in vitro transcription technology , ...
... RNAi , screens with siRNA libraries, Ambion scientists identified ... screen results. , ... Reduce siRNA concentration Use , ... Correct for cell number Note ...
Cached Biology Technology:RNAi for High Throughput Analysis 2RNA Amplification Just Got Better: MessageAmp II 2RNA Amplification Just Got Better: MessageAmp II 3RNA Amplification Just Got Better: MessageAmp II 4RNA Amplification Just Got Better: MessageAmp II 5Recommendations for Successful siRNA Library Screens 2Recommendations for Successful siRNA Library Screens 3Recommendations for Successful siRNA Library Screens 4Recommendations for Successful siRNA Library Screens 5Recommendations for Successful siRNA Library Screens 6Recommendations for Successful siRNA Library Screens 7Recommendations for Successful siRNA Library Screens 8
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... December 19, 2011. Jordan Grafman, PhD, director of traumatic ... Humboldt Research Award from the Alexander von Humboldt Foundation. ... scientists and renowned investigators like Dr. Grafman, who specializes ... cognitive neuroplasticity. "We are pleased to announce ...
... German . For years, Mrs. S. suffered ... rooms, one doctor diagnosed Lyme borreliosis an infectious disease transmitted ... spread throughout the entire body. Mrs. S. is not alone ... all, or is not properly treated. Doctors are provided with no ...
... materials in butanol production have so far been starch ... point in the Aalto University study was to use ... not compete with food production. Another ... modern pulp - and biotechnology. Finland,s advanced forest industry ...
Cached Biology News:Kessler Foundation neuroscientist Jordan Grafman receives Humboldt Research Award 2First aid after tick bites 2Chemicals and biofuel from wood biomass 2
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)...
... dye terminators, template DNA, primers, salts or ... products have proved critical for both standard ... to work with dye terminator cycle sequencing ... The unique uniformity of the magnetic paeticles ...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
X-gal,1g...
Biology Products: